Beacon Biosignals Advances At-Home AI Monitoring of Brain Activity During Sleep

Beacon Biosignals, co-founded by Jake Donoghue and Jarrett Revels, is working to decode the complexities of brain activity by harnessing artificial intelligence to monitor patients while they sleep at home. The company’s core innovation, a lightweight headband using electroencephalogram (EEG) technology, allows for unobtrusive and clinical-grade measurement of neurological function outside the traditional sleep laboratory.

Machine learning algorithms, a subset of AI systems that learn from data patterns, process the collected brain signals to detect subtle neurological changes often linked to disease progression. This data-driven approach is especially significant for identifying early-stage neurological disorders, optimizing clinical trials, and assessing emerging therapies. According to Beacon’s CEO Donoghue, bringing clinical-grade EEG into the home shifts sleep studies from constrained lab environments to scalable, continuous sources of high-quality data.

Beacon’s technology is already in use globally, having participated in more than 40 clinical trials focused on conditions such as major depressive disorder, schizophrenia, narcolepsy, idiopathic hypersomnia, Alzheimer’s disease, and Parkinson’s disease. The company partners with pharmaceutical firms to monitor drug effects on the brain and generate longitudinal datasets—a record of patient data over time—that could serve as a foundation for new diagnostic tools.

The company's ongoing collection and analysis of EEG data aim to build a comprehensive foundation model of the brain, supporting novel disease discovery and tracking the heterogeneity of disease progression. Donoghue notes that standard imaging or genetic sequencing cannot capture the dynamic nature of brain activity, particularly its electrical properties, and emphasizes the need for scalable tools that can detect emerging subgroups of diseases.

The initiative is rooted in Donoghue’s clinical training and research at MIT and Harvard, where he identified the gap in precision monitoring for neurological conditions compared to fields like cardiology. He observed that sleep is a period rich in neural activity and particularly amenable to AI analysis. By capturing sleep architecture—patterns of brain waves during different sleep stages—Beacon’s platform can flag minute changes that may precede symptoms of cognitive or neurodegenerative diseases.

Recent clinical trials have demonstrated the utility of this approach in early detection of disorders such as Alzheimer’s and Parkinson’s, where changes in sleep patterns can manifest well before traditional symptoms arise. In one example, the company’s AI system analyzed rapid-eye-movement and slow-wave sleep to identify early changes correlating to disease.

To expand its reach, Beacon acquired a U.S.-based at-home sleep apnea testing company in 2023, increasing access to comprehensive neurological testing for more than 100,000 patients annually. The company also secured $97 million in new funding, accelerating its efforts to build longitudinal brain health records that could one day transform routine sleep studies into proactive neurological screening.

Beacon Biosignals’ approach highlights how AI and wearable technology are reshaping the collection and interpretation of complex medical data, pointing toward earlier and more personalized treatments for brain diseases.

Reference: news.mit.edu